
Ocugen, Inc. Announces Dosing Completion in the Phase 2 ArMaDa Clinical Trial for OCU410—a Multifunctional Modifier Gene Therapy for the Treatment of Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
<a href="https://news.google.com/rss/articles/CBMivAFBVV95cUxQdjcwQzVkd1FKeWZWOTc1RmZ2UXFZWEdTU21xVk5uSXhaMUxKZ2xpWUdyZHNOQXVwY1JNd2V1SHdaN0xIcWZIR01VcjJpNlRuV1JJNldSSFM3MEh0ZnFyUDRBX1NVdUVmOGRZaFRTdzBNbHFRTFQwdnd0X1BrQTJQTUlpLXM4LTE5RXFSWTU5c1B2WUhuUnprdlRKd2o2QTZINkNvV0twZjczUFBXNkgyTU9OVTNlVnIyd0dUSQ?oc=5" target="_blank">Ocugen, Inc. Announces Dosing Completion in the Phase 2 ArMaDa Clinical Trial for OCU410—a Multifunctional Modifier Gene Therapy for the Treatment of Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration</a>&nbsp;&nbsp;<font color="#6f6f6f">Ocugen, Inc.</font>